Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
03 April 2020Website:
http://zentalis.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 37 min agoDividend
Analysts recommendations
Institutional Ownership
ZNTL Latest News
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) (NASDAQ: ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
NEW YORK , June 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
NEW YORK, NY / ACCESSWIRE / June 21, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Zentalis' (ZNTL) three studies evaluating azenosertib for three different cancer indications face the FDA's partial clinical hold following the death of two patients.
ATLANTA, June 18, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Zentalis Pharmaceuticals, Inc. (“Zentalis” or the “Company”) (NASDAQ: ZNTL) complied with federal securities laws. On June 18, 2024, Zentalis announced that “the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC).” Following this news, the price of the Company's stock dropped.
FDA has placed a partial clinical hold on ZN-c3-001, DENALI and TETON monotherapy studies of azenosertib Monotherapy data to be presented in the second half of 2024 Conference call to be held today, June 18, 8:00 am ET SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on the following studies of azenosertib: the Phase 1 ZN-c3-001 dose-escalation study in solid tumors, the Phase 2 ZN-c3-005 (DENALI) study in platinum-resistant ovarian cancer (PROC) and the Phase 2 ZN-c3-004 (TETON) study in uterine serous carcinoma (USC). This action follows two recent deaths due to presumed sepsis in the DENALI study.
NEW YORK and SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Luke Walker, M.D., to its Board of Directors. Dr. Walker is the Chief Medical Officer of Harpoon Therapeutics, a subsidiary of Merck & Co., Inc., Rahway, NJ, and brings nearly three decades of experience as a practicing oncologist and drug developer advancing new cancer therapies.
Administration of azenosertib combined with gemcitabine was well tolerated and resulted in clinically meaningful increase in event-free survival compared to historical comparators
Zentalis Pharmaceuticals, Inc. anticipates receiving final results from a phase 1b trial combining azenosertib and gemcitabine for osteosarcoma treatment by mid-2024. In a separate phase 1 study involving azenosertib as a monotherapy for platinum-resistant or refractory ovarian cancer and uterine serous carcinoma patients, a 37% overall response rate was achieved. The company plans to commence a clinical trial for first-line maintenance therapy in platinum-sensitive ovarian cancer patients in 2025, with details of the trial design expected to be disclosed in late 2024.
The consensus price target hints at a 136.4% upside potential for Zentalis Pharmaceuticals, Inc. (ZNTL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
What type of business is Zentalis Pharmaceuticals?
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.
What sector is Zentalis Pharmaceuticals in?
Zentalis Pharmaceuticals is in the Healthcare sector
What industry is Zentalis Pharmaceuticals in?
Zentalis Pharmaceuticals is in the Biotechnology industry
What country is Zentalis Pharmaceuticals from?
Zentalis Pharmaceuticals is headquartered in United States
When did Zentalis Pharmaceuticals go public?
Zentalis Pharmaceuticals initial public offering (IPO) was on 03 April 2020
What is Zentalis Pharmaceuticals website?
https://zentalis.com
Is Zentalis Pharmaceuticals in the S&P 500?
No, Zentalis Pharmaceuticals is not included in the S&P 500 index
Is Zentalis Pharmaceuticals in the NASDAQ 100?
No, Zentalis Pharmaceuticals is not included in the NASDAQ 100 index
Is Zentalis Pharmaceuticals in the Dow Jones?
No, Zentalis Pharmaceuticals is not included in the Dow Jones index
When does Zentalis Pharmaceuticals report earnings?
The next expected earnings date for Zentalis Pharmaceuticals is 09 August 2024